Entrada Therapeutics to Participate in Guggenheim Genomic Medicines and Rare Disease Conference
Entrada Therapeutics (Nasdaq: TRDA), a biopharmaceutical company, announced participation of CEO Dipal Doshi in a virtual fireside chat at the Guggenheim Genomic Medicines and Rare Disease Conference on April 4, 2023 at 9:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Entrada Therapeutics (Nasdaq: TRDA), a biopharmaceutical company, announced participation of CEO Dipal Doshi in a virtual fireside chat at the Guggenheim Genomic Medicines and Rare Disease Conference on April 4, 2023 at 9:00 a.m. ET. This event aims to highlight Entrada's innovative approach to Endosomal Escape Vehicle (EEV™) therapeutics, which targets previously inaccessible intracellular areas for drug delivery. Interested stakeholders can access the live webcast on Entrada's Investor Relations page, with a replay available for 90 days post-event.
Entrada is developing therapies for various diseases, including neuromuscular and immunological conditions, with specific focus on treatments for Duchenne muscular dystrophy.
Details
News Market Reaction – TRDA
The recorded move for TRDA in the trading session of this news was -0.87%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™) therapeutics as a new class of medicines, today announced that Dipal Doshi, President and Chief Executive Officer, will participate in a virtual fireside chat during the Guggenheim Genomic Medicines and Rare Disease Conference on Tuesday, April 4, 2023 at 9:00 a.m. Eastern Time.
A live webcast will be available on the Investor Relations section of the Company’s website at www.entradatx.com. A replay will be available on the Entrada website for 90 days following the event.
About Entrada Therapeutics
Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicle (EEV™)-therapeutics, to engage intracellular targets that have long been considered inaccessible and undruggable. The Company’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Through its proprietary, highly versatile and modular EEV platform, Entrada is building a robust development portfolio of RNA-, antibody- and enzyme-based programs for the potential treatment of neuromuscular, immunological, ocular and metabolic diseases, among others. The Company’s lead oligonucleotide programs include ENTR-601-44 and ENTR-601-45 for the potential treatment of people living with Duchenne who are exon 44 and 45 skipping amenable, respectively, as well as our partnered candidate ENTR-701 targeting myotonic dystrophy type 1 (DM1).
For more information about Entrada, please visit our website, www.entradatx.com, and follow us on Twitter and LinkedIn.
Investor and Media Contact
Karla MacDonald
Chief Corporate Affairs Officer
kmacdonald@entradatx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.